- Novel
flow-through invention offers critical enablement for future system design
strategies for groundbreaking biotherapeutics research, as well as drug
discovery & development
- Development
of next generation Barocycler instruments to allow “hands-free” sample
processing that will increase accuracy, reduce costs and avoid
contamination
- Global
sample preparation market projected to reach $8.2 billion by 2024
- Global
proteomics market projected to reach $21.87 billion in 2021
- PBIO’s
innovative ultra-shear pressure-based platform technology (UST) being used
in federally-funded food safety and preservation development program at
Ohio State University
- Potential
applications for UST include pharmaceuticals, nutraceuticals, food and
beverages, lubricants, paints and cosmetics
Pressure BioSciences Inc. (“PBI”) (OTCQB: PBIO), a leader in
the development and sale of broadly enabling, pressure-based instruments,
consumables and platform solutions to the worldwide life sciences industry, has
added another patent to its intellectual property portfolio, bringing the total
to 21 patents. Issued as U.S. Patent 9995661 and titled “Flow-through High
Hydrostatic Pressure Microfluidic Sample Preparation Device and Related Methods
Therefor,” this new patent is a significant development in the company’s
strategic plan to develop automated “hands-free” sample handling for the next
generation of PBI’s high-pressure sample preparation platform systems, a news
release states (http://ibn.fm/gqp34).
The global sample preparation market is projected to reach
$8.2 billion by 2024, according to a report by
TransparencyMarketResearch (http://ibn.fm/wCaOd).
Pressure BioSciences’ product line is led by its newly released,
next-generation Barocycler 2320EXTREME instrument system, which can be
used to exquisitely control the sample preparation process. Based on the
company’s patented and enabling pressure cycling technology (PCT) platform,
over 300 Barocycler systems have been installed in approximately 200 academic,
government, pharmaceutical and biotech research laboratories worldwide.
These laboratories use the PCT instrument system for multiple applications,
including the preparation of samples for biomarker and target discovery, soil
& plant biology, anti-bioterror and forensics studies. There are over 100
independent scientific publications highlighting the advantages of the PCT
system in such studies, many from worldwide key opinion leaders.
“This long-anticipated patent is a very important
development for the Company on multiple fronts, and the timing of its issuance
could not be better,” Dr. Alexander Lazarev, PBI’s vice president of research
and development, stated in the release. “This invention also enables a unique
capability for maintaining high pressure in a flow-through format (rather than
the current batch processing), which we expect will facilitate the development
of new, automated continuous process monitoring tools applicable to diverse
segments of the life sciences industry.”
The invention’s novel flow-through concept offers critical
enablement for future system design strategies for epitope characterization,
Lazarev noted. An epitope is the antibody binding site on an antigen capable of
eliciting an immune response. “This is an emerging area in development and
production of biotherapeutics that could revolutionize personalized therapy for
numerous medical conditions, including autoimmune diseases and a variety of
rare medical disorders,” Lazarev explained.
PBI’s latest, patented invention will allow for further
development of a much sought-after, hands-free, automated workflow, providing
valuable enhancements in efficiencies, throughput and contamination avoidance
for the company’s instrument and consumable product lines, Richard T.
Schumacher, president and CEO of PBI, added.
“We also believe this invention will accelerate our
expansion into larger scale applications in multiple major business segments
for the Company, particularly in the rapidly growing field of proteomics
research,” Schumacher said. “Growth in proteomics and other additional areas
should further cement and expand market acceptance and recognition for PBI’s
innovative and enabling pressure-based platform technologies and spur concomitant
growth in revenue and shareholder value.”
According to a market report by Research and Markets, the
worldwide biopharmaceuticals market in 2014 reached a valuation of $160.44
billion.
Pressure BioSciences is forecast to grow at a compound
annual growth rate (CAGR) of 76 percent in the next five fiscal years from 2018
to 2022, according to a Zacks Research Report issued on July 26, 2018 (http://ibn.fm/IyKn9). In the
Zacks Small-Cap Research Report, the company’s fair value for PBIO shares was
raised to $12/share from a previous $10/share. Zacks’ optimism regarding
Pressure BioSciences is tied to a number of recent achievements and
collaborative research programs, expansion of the company’s sales and marketing
capabilities and a newly established multinational co-marketing partner, ISS
Inc.
The future looks bright for the company based on the
expected growth in sales of its PCT-based instrument systems. PBI’s revenue
should be additionally impacted by the development of its newest high-pressure
technology platform, ultra shear technology (UST). UST offers the potential to
produce highly stable, clean and cost-effective nanoemulsions that facilitate
the production of food products with enhanced shelf lives without the need for
chemicals or preservatives, as detailed in a recent article (http://ibn.fm/gcKNZ). The
company believes that its UST technology platform can be applied across a
multitude of industries seeking to satisfy consumer demand for chemical- and
preservative-free food products that have longer shelf-lives, greater safety
and do not require refrigeration until opened. These areas include
pharmaceuticals, nutraceuticals, cosmetics, paints and industrial lubricants.
For more information, visit the company’s website at www.PressureBioSciences.com
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment